Advertisement

Valerian

  • Brian J. Isetts
Part of the Forensic Science and Medicine book series (FSM)

Abstract

Valerian is a unique herb with a long history of use through western Europe as a sedative and hypnotic. A variety of pharmacologically active components are likely responsible for its clinical effects including volatile oils, monoterpenes, valepotriates, and sesquiterpenes. Valerenic acid, a sesquiterpene component of valerian, is postulated to produce sedation through inhibition of the breakdown of gamma-amino butyric acid. The herb is well tolerated, and side effects have been mild and self-limiting in most cases. Isolated reports of liver damage have occurred with valerian being a concomitantly consumed agent, yet anecdotal cases of attempted intentional self-poisoning with the herb have not resulted in fatality and long-term follow-up for subsequent hepatotoxicity in a number of these patients has not revealed liver abnormalities. The herb’s postitive safety profile and demonstrated effectiveness in treating insomnia contributes to its popularity.

Key Words

Valerenic acid valepotriates monoterpenes sesquiterpenes anxiolytic hypnotic 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Combest WL. Valerian. US Pharmacist 1997;22:62–68.Google Scholar
  2. 2.
    Anonymous. Valerian. Lawrence Review of Natural Products. St. Louis: Facts and Comparisons, 1991.Google Scholar
  3. 3.
    Houghton P. Valerian. Pharm J 1994;253:95–96.Google Scholar
  4. 4.
    United States Pharmacopeial Convention (USP). Valerian. Botanical Monograph Series. Rockville: United States Pharmacopeial Convention, 1998.Google Scholar
  5. 5.
    Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999; 56:125–138.PubMedGoogle Scholar
  6. 6.
    Houghton PJ. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 1999;51:505–512.PubMedCrossRefGoogle Scholar
  7. 7.
    Natural medicines comprehensive database online, 2004. http://www.naturaldatabase.com/. Date accessed: June 9, 2006.
  8. 8.
    Heiligenstein E, Guenther G. Over-the-counter psychotropics: a review of melatonin, St. Johns’s wort, valerian, and kava-kava. J Am Col Health 1998;46:271–276.CrossRefGoogle Scholar
  9. 9.
    Blumenthal M. Valerian root. The complete German Commission E monographs. Austin: American Botanical Council, 1998.Google Scholar
  10. 10.
    Donath F, Quispe S, Diefenbach K, et al. Critical evaluation of the effect of valerian on sleep structure and sleep quality. Pharmacopsychiatry 2000;33:47–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 1982;17:65–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985;2:144–148.PubMedCrossRefGoogle Scholar
  13. 13.
    Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology 1985;87:406–409.PubMedCrossRefGoogle Scholar
  14. 14.
    Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989;32:1065–1066.PubMedCrossRefGoogle Scholar
  15. 15.
    Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 1994;27:147–151.PubMedGoogle Scholar
  16. 16.
    Leuschner J, Muller J, Rudmann M. Characterization of the central nervous depressant activity of a commercially available valerian root extract. Arzneim Forsch 1993;43:638–641.Google Scholar
  17. 17.
    Hendriks H, Bos R, Woerdenbag HJ, Koster AS. Central nervous depressant activity of valerenic acid in the mouse. Planta Med 1985;51:28–31.PubMedCrossRefGoogle Scholar
  18. 18.
    Mennini P, Bernasconi P, Bombardelli E, Morazzoni P. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 1993;64:291–300.Google Scholar
  19. 19.
    Cavadas C, Araujo I, Cotrim MD, et al. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GAB AA receptor in rat brain. Arzneim Forsch 1995;45:753–755.Google Scholar
  20. 20.
    Santos MS, Ferreira F, Faro C, et al. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H] GABA release in synaptosomes. Planta Med 1994;60:475–476.PubMedCrossRefGoogle Scholar
  21. 21.
    Santos MS, Ferreira F, Cunha AP, Carvalho AP, Macedo T. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med 1994;60:278–279.PubMedCrossRefGoogle Scholar
  22. 22.
    Wagner J, Wagner ML, Hening WA, Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32:680–691.PubMedCrossRefGoogle Scholar
  23. 23.
    Tyler VE, ed. The Honest Herbal, 3rd edition, Binghamton: Pharmaceutical Products Press, 1993.Google Scholar
  24. 24.
    Houghton P. The biological activity of valerian and related plants. J Ethnopharmacol 1988;22:121–142.PubMedCrossRefGoogle Scholar
  25. 25.
    Oshima Y, Matsuoka S, Ohizumi Y. Antidepressant principles of Valeriana fauriei roots. Chem Pharmacol Bull 1995;43:169–170.Google Scholar
  26. 26.
    Sakamoto T, Mitani Y, Nakajima K. Psychotropic effevts of Japanese valerian root extract. Chem Pharmacol Bull 1992;40:758–761.Google Scholar
  27. 27.
    Muller SF, Klement S. A combination of valerian and umun balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine 2006;13:383–387.PubMedCrossRefGoogle Scholar
  28. 28.
    Cropley M, Cave Z, Ellis J, Middleton RW. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res 2002; 16:23–27.PubMedCrossRefGoogle Scholar
  29. 29.
    Kohnen R, Oswald WD. Effects of valerian, propranolol and combinations on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry 1988;21:477–478.CrossRefGoogle Scholar
  30. 30.
    Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002; 16:650–654.PubMedCrossRefGoogle Scholar
  31. 31.
    Hazelhoff B, Malingre TM, Meijer DKF. Antispasmodic effects of valeriana compounds: and in vivo and in vitro study on the guinea-pig ileum. Arch Int Pharmacodyn 1982;257:274–287.PubMedGoogle Scholar
  32. 32.
    Anderson GD, Elmer GW, Kantor ED, Templeton IE, Vitiello MV. Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytother Res 2005;19:801–803.PubMedCrossRefGoogle Scholar
  33. 33.
    Czeizel AE, Tomcsik M, Timar L. Teratologic evaluation of 178 infants born to mothers who attempted suicide by drugs during pregnancy. Obstet Gynecol 1997;90:195–201.PubMedCrossRefGoogle Scholar
  34. 34.
    Czeizel A, Szentesi I, Szekeres H, Molnar G, Glauber A, Bucski P. A study of adverse effects on the progeny after intoxication during pregnancy. Ach Toxicol 1988;62:1–7.CrossRefGoogle Scholar
  35. 35.
    Tufik S, Fujita K, Seabra MDV, Leticia LL. Effects of a prolonged administration of valepotriates in rats on the mothers and their offspring. J Ethnopharmacol 1994;41:39–44.PubMedCrossRefGoogle Scholar
  36. 36.
    Petkov V. Plants with hypotensive, antiatheromatous and coronarodilatating action. Am J Chin Med 1979;7:197–236.PubMedCrossRefGoogle Scholar
  37. 37.
    Rosecrans Ja, Defeo JJ, Youngken HW. Pharmacological investigation of certain Valeriana officinalis L. extracts. J Pharmaceut Sci 1961;50:240–244.CrossRefGoogle Scholar
  38. 38.
    Tortarolo M, Braun R, Hubner GE, Maurer HR. In vitro effects of epoxide-bearing valepotriates on mouse early hematopoietic progenitor cells and human T-lymphocytes. Arch Toxicol 1982;51:37–42.CrossRefGoogle Scholar
  39. 39.
    Bounthanh C, Richert L, Beck JP, Haag-Berrurier M, Anton R. The action of valepotriates on the synthesis of DNA and proteins of cultured hepatoma cells. Planta Med 1983;49:138–142.CrossRefGoogle Scholar
  40. 40.
    MacGregor FB, Abernethy VE, Dahabra S, Cobden I, Hayes PC. Hepatotoxicity of herbal remedies. Br Med J 1989;299:1156–1157.Google Scholar
  41. 41.
    Chan TYK, Tang CH, Crichley J. Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian). Postgrad Med J 1995;71:227–228.PubMedGoogle Scholar
  42. 42.
    Chan TYK. An assessment of the delayed effects associated with valerian overdose [letter]. Int J Clin Pharmacol Ther 1999;36:569.Google Scholar
  43. 43.
    Willey LB, Mady SP, Cobaugh DG, Wax PM. Valerian overdose: a case report. Vet Hum Toxicol 1995;37:364–365.PubMedGoogle Scholar
  44. 44.
    Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal [letter]. JAMA 1998;280:1566–1567.PubMedCrossRefGoogle Scholar
  45. 45.
    Andreatini R, Loire JR. Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur J Pharmacol 1994;260:233–235.PubMedCrossRefGoogle Scholar
  46. 46.
    Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commerical herbal extracts and tinctures. Phytomedicinc 2000; 7:237–282.Google Scholar
  47. 47.
    Lefebrve T, Foster BC, Drouin CE, Livesey JF, Jordan SA. In vitro activity of commerical valerian root extracts against cytochrome P450 3A4. J Pharm Pharmaceuti Sci 2004; 7:265–273.Google Scholar
  48. 48.
    Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-times doses of valerian (Valeriana officianalis) had minimal effects of Cyp3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32:1333–1336.PubMedCrossRefGoogle Scholar
  49. 49.
    Mkrtchyan A, Panosyan V, Panossian A, Wikman G, Wagner H. A phase I clinical study of Andrographis paniculata fixed combination Kan Jang versus ginseng and valerian on the semen quality of healthy male subjects. Phytomedicinc 2005; 12:403–409.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Brian J. Isetts

There are no affiliations available

Personalised recommendations